TGTX Q2 2025 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$141M+92.1% YoY

Gross Profit

$122M86.6% margin

Operating Income

$35M24.7% margin

Net Income

$28M20.0% margin

EPS (Diluted)

$0.17

QoQ Revenue Growth

+16.8%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$7M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$703M

Total Liabilities

$426M

Stockholders' Equity

$276M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$141M	$73M	+92.1%
Gross Profit	$122M	$65M	+87.5%
Operating Income	$35M	$9M	+295.2%
Net Income	$28M	$7M	+309.8%

Revenue Segments

Product

$139M98%

License Revenue

$2M2%